Bio-Rad Laboratories (BIO) RBC Capital Markets Global Healthcare Conference 2026 summary

Recent performance and key growth drivers

• Achieved 24% year-over-year growth in digital PCR instruments, driven by the QX700 series from the Stilla acquisition, which is ahead of accretiveness schedule.

• Successfully ported 99% of over 400,000 assays to the digital PCR platform, reinforcing the QX700 value proposition.

• Quality controls in diagnostics showed mid-single-digit growth and are seen as a global opportunity with attractive margins.

• Free cash flow reached $78 million, with $48 million in share repurchases, despite challenging end markets.

• Blood typing products performed well globally, though Middle East conflict impacted regional results.

Regional and segment trends

• Middle East represents about 9% of diagnostics revenue; growth is expected to resume post-conflict.

• China business remains stable, with strong quality controls and a 50/50 split between tools and diagnostics.

• New China manufacturing capability for select SKUs was established in 120 days to support local tenders and long-term growth.

Life sciences and biopharma market dynamics

• U.S. academic and government markets are soft due to slow NIH fund disbursement; Europe also shows softening.

• Consumable pull-through is slowing globally, attributed to reduced lab activity.

• Applied markets like food science remain stable, while Western blotting faces headwinds from fewer new lab startups.

• Large pharma is stable, but early-stage biopharma remains soft; slight improvement expected later in the year.